CTSO
Cytosorbents Corporation NASDAQ Listed Aug 8, 2006$0.61
Mkt Cap $38.3M
52w Low $0.50
12.4% of range
52w High $1.39
50d MA $0.66
200d MA $0.77
P/E (TTM)
-4.7x
EV/EBITDA
-4.9x
P/B
6.5x
Debt/Equity
4.9x
ROE
-138.9%
P/FCF
-3.2x
RSI (14)
—
ATR (14)
—
Beta
1.48
50d MA
$0.66
200d MA
$0.77
Avg Volume
84.5K
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
305 College Road East · Princeton, NJ 08540 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.05 | -0.09 | -80.0% | 0.67 | -9.0% | -10.6% | -11.7% | -16.6% | -15.6% | -18.5% | — |
| Nov 13, 2025 | AMC | -0.06 | -0.04 | +33.3% | 0.67 | +2.2% | -0.8% | -1.4% | -6.6% | -4.0% | -6.5% | — |
| Aug 7, 2025 | AMC | -0.07 | -0.05 | +28.6% | 0.89 | +5.2% | +12.0% | +34.3% | +18.7% | +20.9% | +27.6% | — |
| May 14, 2025 | AMC | -0.08 | -0.06 | +25.0% | 0.81 | +4.1% | +3.3% | +11.4% | +5.2% | +4.0% | +7.7% | — |
| Mar 31, 2025 | AMC | -0.07 | -0.03 | +57.1% | 1.00 | +0.0% | +0.0% | +0.0% | -1.0% | -3.0% | -0.9% | — |
| Nov 7, 2024 | AMC | -0.07 | -0.08 | -14.3% | 0.90 | -1.4% | -18.1% | +3.0% | +7.4% | +2.5% | +5.2% | — |
| Aug 13, 2024 | AMC | -0.09 | -0.08 | +11.1% | 0.90 | -1.1% | +8.0% | +14.0% | +16.2% | +17.3% | +17.3% | — |
| May 9, 2024 | AMC | -0.12 | -0.12 | +0.0% | 0.81 | +2.5% | +12.3% | +3.1% | +2.7% | +3.8% | +7.0% | — |
| Mar 14, 2024 | AMC | -0.14 | -0.12 | +14.3% | 0.97 | -1.0% | -9.3% | -0.4% | -8.2% | -10.4% | -11.3% | — |
| Nov 9, 2023 | AMC | -0.12 | -0.21 | -75.0% | 1.26 | +14.3% | +0.8% | +2.4% | +1.6% | -7.1% | -12.7% | — |
| Aug 1, 2023 | AMC | -0.11 | -0.14 | -27.3% | 3.62 | -2.5% | -7.5% | -12.2% | -11.6% | -13.8% | -17.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.61 | -9.0% | -10.6% | -11.7% | -16.6% | -15.6% | -18.5% |
| Jan 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.70 | +4.0% | +4.5% | +8.8% | +7.0% | +2.9% | +4.6% |
| Dec 16 | D. Boral Capital | Maintains | Buy → Buy | — | $0.63 | $0.64 | +2.4% | +2.2% | +2.7% | +3.0% | +1.7% | +22.3% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +2.2% | -0.8% | -1.4% | -6.6% | -4.0% | -6.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.67 | $0.68 | +2.2% | -0.8% | -1.4% | -6.6% | -4.0% | -6.5% |
| Sep 16 | D. Boral Capital | Maintains | Buy → Buy | — | $0.92 | $0.91 | -1.1% | -0.7% | -1.2% | +1.9% | +2.8% | +5.5% |
| Aug 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.01 | -6.5% | -17.2% | -21.9% | -15.5% | -16.1% | -13.9% |
| Aug 8 | D. Boral Capital | Maintains | Buy → Buy | — | $0.89 | $0.94 | +5.2% | +12.0% | +34.3% | +18.7% | +20.9% | +27.6% |
| Jul 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.02 | -1.0% | +1.0% | -2.9% | -1.0% | -2.9% | -8.4% |
| Jun 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.18 | -1.7% | +0.0% | -1.7% | +2.5% | +6.7% | +7.5% |
| May 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.81 | $0.84 | +4.1% | +3.3% | +11.4% | +5.2% | +4.0% | +7.7% |
| May 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.81 | $0.84 | +4.1% | +3.3% | +11.4% | +5.2% | +4.0% | +7.7% |
| May 2 | D. Boral Capital | Maintains | Buy → Buy | — | $1.01 | $0.92 | -8.9% | -6.9% | -10.1% | -11.9% | -12.6% | -13.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.00 | $1.00 | +0.0% | -1.0% | -3.0% | -0.9% | -4.0% | -6.0% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $1.00 | $1.00 | +0.0% | +0.0% | +0.0% | -1.0% | -3.0% | -0.9% |
| Feb 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.09 | $1.09 | +0.0% | +0.0% | +0.9% | -1.8% | -2.8% | -5.5% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | +0.2% | +12.0% | +10.9% | +15.2% | +10.9% | +9.8% |
| Jan 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.92 | $0.88 | -4.5% | +1.8% | +13.0% | +9.8% | +5.4% | +1.9% |
| Nov 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.93 | $0.95 | +2.2% | +4.3% | -0.4% | +2.1% | -3.8% | +0.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.74 | $0.82 | +10.8% | +25.7% | +31.1% | +25.1% | +28.4% | +20.9% |
| Nov 8 | EF Hutton | Maintains | Buy → Buy | — | $0.90 | $0.89 | -1.4% | -18.1% | +3.0% | +7.4% | +2.5% | +5.2% |
| Nov 4 | EF Hutton | Maintains | Buy → Buy | — | $1.00 | $1.00 | -0.5% | -12.9% | -13.8% | -8.1% | -9.7% | -26.0% |
| Oct 22 | EF Hutton | Maintains | Buy → Buy | — | $1.05 | $1.06 | +1.0% | -1.0% | +0.0% | +0.0% | -1.0% | -3.8% |
| Oct 1 | EF Hutton | Maintains | Buy → Buy | — | $1.50 | $1.54 | +2.7% | -10.0% | -10.7% | -18.0% | -20.7% | -24.7% |
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.90 | $0.89 | -1.1% | +8.0% | +14.0% | +16.2% | +17.3% | +17.3% |
| Aug 14 | EF Hutton | Maintains | Buy → Buy | — | $0.90 | $0.89 | -1.1% | +8.0% | +14.0% | +16.2% | +17.3% | +17.3% |
| May 15 | B. Riley Securities | Maintains | Buy → Buy | — | $0.83 | $0.83 | -0.2% | +1.1% | +4.2% | +16.4% | +17.8% | +13.0% |
| May 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.93 | $0.93 | +0.0% | +0.2% | -6.2% | -12.9% | -2.2% | -10.2% |
| Mar 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.97 | $0.96 | -1.0% | -9.3% | -0.4% | -8.2% | -10.4% | -11.3% |
| Dec 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | +1.8% | -1.8% | -8.3% | -11.5% | -15.6% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.53 | -2.5% | -7.5% | -12.2% | -11.6% | -13.8% | -17.1% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +16.5% | +16.5% | +17.3% | +19.4% | +24.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.58 | $3.66 | +2.2% | +0.0% | -8.5% | -4.2% | -10.6% | -9.2% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.60 | -17.9% | -15.9% | -20.5% | -19.0% | -25.1% | -23.6% |
| May 4 | B. Riley Securities | Maintains | Buy → Buy | — | $2.18 | $1.97 | -9.6% | -2.8% | -9.6% | -14.7% | -13.8% | -5.0% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $1.97 | -9.6% | -2.8% | -9.6% | -14.7% | -13.8% | -5.0% |
| Sep 17 | Jefferies | Maintains | Buy → Buy | — | $8.31 | $8.48 | +2.0% | +5.1% | +4.3% | +0.4% | -1.4% | -6.3% |
| Sep 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.44 | $8.69 | +3.0% | +0.6% | +0.7% | -8.6% | -11.6% | -12.7% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | +11.3% | +13.3% | +13.3% | +11.7% |
| May 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | +11.3% | +13.3% | +13.3% | +11.7% |
| May 6 | B. Riley Securities | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | +11.3% | +13.3% | +13.3% | +11.7% |
| May 6 | B. Riley FBR | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | +11.3% | +13.3% | +13.3% | +11.7% |
| Aug 8 | Maxim Group | Maintains | Buy → Buy | — | $4.75 | $5.25 | +10.5% | +4.2% | -2.1% | -5.3% | -3.2% | +0.0% |
| Jun 7 | Cowen & Co. | Maintains | Outperform → Outperform | — | $3.95 | $4.15 | +5.1% | +2.5% | +1.3% | +0.0% | -1.3% | -8.9% |
| Oct 26 | Aegis Capital | Maintains | Buy → Buy | — | $5.90 | $5.95 | +0.8% | +0.0% | -2.5% | +0.0% | +0.0% | -1.7% |
| Oct 7 | B. Riley FBR | Maintains | Buy → Buy | — | $5.63 | $5.87 | +4.3% | -0.9% | +5.7% | +6.6% | +1.2% | -1.4% |
| Mar 5 | MLV & Co. | Maintains | Buy → Buy | — | $10.87 | $11.09 | +2.0% | -0.6% | +4.9% | +7.5% | +2.5% | +4.4% |
| Feb 25 | WBB Securities | Maintains | Speculative Buy → Buy | — | $11.11 | $11.32 | +1.9% | +7.3% | +2.3% | +3.3% | +2.5% | -1.6% |
No insider trades available.
8-K
Unknown — 8-K Filing
Cattso Group's stock price fell below Nasdaq's $1 minimum, risking delisting unless it recovers by March 2026, potentially destroying shareholder value if compliance isn't achieved.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CTSO's modest 4% revenue growth masks zero constant-currency expansion, while operating losses persist at $14.7M despite improvement, signaling continued profitability challenges ahead for investors.
Mar 25
Data updated apr 25, 2026 3:51am
· Source: massive.com